• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin as well as a preparation method and application thereof, and belongs to the technical field of drug concentration detection of in vitro diagnostic reagents. The test strip comprises a bottom plate and a sample absorption pad, a fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad which are sequentially overlapped and pasted on the bottom plate. The fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using a vancomycin-bovine serum albumin conjugate as an immunogen. The test strip of the present invention has no cross reaction with various vancomycin analogs, and has the advantages of high detection accuracy and strong specificity.
    公开号:EP3680665A1
    申请号:EP19171924.4
    申请日:2019-04-30
    公开日:2020-07-15
    发明作者:Xiuli Xu；Yanxin Wang；Yuanrong Chang；Jianping Zhou
    申请人:Beijing Diagreat Biotechnologies Co Ltd；
    IPC主号:G01N33-00
    专利说明:
    [0001] This application claims priority to Chinese application number 201910020000.0, filed January 9, 2019 , with a title of TIME-RESOLVED FLUORESCENT IMMUNOCHROMATOGRAPHIC TEST STRIP FOR DETECTING VANCOMYCIN AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF. The above-mentioned patent application is incorporated herein by reference in its entirety. TECHNICAL FIELD
    [0002] The present invention relates to the technical field of drug concentration detection of in vitro diagnostic reagents, and in particular, to a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin as well as a preparation method and application thereof. BACKGROUND
    [0003] Vancomycin is a tricyclic glycopeptide antibiotic that is a preferred antibiotic for clinically treating serious infections caused by Methicillin-Resistant Staphylococcus Aureus (MRS1), Methicillin-Resistant Staphylococcus Epidermidis (MRSE), and Penicillin-Resistant Streptococcus Pneumoniae (PRSP).Vancomycin has a strong bactericidal effect on gram-positive bacteria, but is narrow in therapeutic index and significant in individual metabolic difference, and has significant ototoxicity and nephrotoxicity. Therefore, it is necessary to monitor the blood concentration to adjust the medication.
    [0004] At present, methods for monitoring the concentrations of vancomycin drugs at home and abroad include Thin Layer Chromatography (TL3), Capillary Electrophoresis (CE), High Performance Liquid Chromatography (HPL3), and biochemical methods. However, the methods are not suitable for large-scale clinical promotion. Although Turbidimetric inhibition immuno assay (TI1), homogeneous enzyme immunoassay, chemiluminescence, and fluorescence polarization are currently available on the market for assay of vancomycin, the cost is high, and the methods are monopolized by foreign importers, and cannot meet the ever-increasing demand for clinical monitoring. SUMMARY
    [0005] An objective of the present invention is to provide a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin as well as a preparation method and an application thereof. The test strip has the advantages of high detection accuracy and strong specificity.
    [0006] To achieve the above purpose, the present invention provides the following technical solutions.
    [0007] The present invention provides a preparation method of a vancomycin-bovine serum albumin conjugate, including the following steps:1) mixing a sodium periodate aqueous solution with a vancomycin aqueous solution to carry out a redox reaction to obtain a vancomycin pre-conjugate; 2) mixing bovine serum albumin with a carbonate buffer to obtain a bovine serum albumin solution; and 3) mixing the vancomycin pre-conjugate in step 1) with the bovine serum albumin solution in step 2), and carrying out a coupling reaction to obtain a vancomycin-bovine serum albumin conjugate;steps 1) and 2) are not chronologically limited.
    [0008] Preferably, the time of the coupling reaction in step 3) is 10-15 h, and the temperature of the coupling reaction is 15-37°C.
    [0009] Preferably, the time of the redox reaction in step 1) is 0.8-1.5 h, and the temperature of the redox reaction is 18-26°C.
    [0010] The present invention provides a vancomycin-bovine serum albumin conjugate prepared by the above preparation method.
    [0011] The present invention provides a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin, comprising a bottom plate and a sample absorption pad, a fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad which are sequentially overlapped and pasted on the bottom plate, wherein the fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using the above vancomycin-bovine serum albumin conjugate as an immunogen.
    [0012] Preferably, the diameter of the fluorescent microsphere is 100-300 nm, and the fluorescent microsphere has a carboxyl group on the surface.
    [0013] Preferably, the fluorescent microsphere is a microsphere in which polystyrene is coated with rare earth ion Eu+.
    [0014] Preferably, a preparation method of the fluorescent microsphere-labeled vancomycin monoclonal antibody comprises the following steps: I. mixing a fluorescent microsphere suspension, an MES buffer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide for activation treatment to obtain an activated fluorescent microsphere; and II. mixing the activated fluorescent microsphere in step I with the vancomycin monoclonal antibody for coupling to obtain a fluorescent microsphere-labeled vancomycin monoclonal antibody.
    [0015] The present invention provides an application of the above test strip in detection of vancomycin, comprising the following steps: adding pure vancomycin of different concentrations to a human serum matrix excluding vancomycin to prepare a calibrator, the concentrations of vancomycin in the calibrator being 40 µg/mL, 20 µg/mL, 10 µg/mL, 5 µg/mL, and 0 µg/mL, sequentially; diluting the calibrator 100-1,000 times, and then loading to a sample absorption pad of the test strip for immunochromatography, and determining a ratio (a T/C ratio) of the time-resolved fluorescent intensity of a detection area to the time-resolved fluorescent intensity of a quality control area to obtain a function relation of the concentration of the calibrator and the T/C ratio; and taking a sample to be tested, and loading same to the sample absorption pad of the test strip for immunochromatography, determining a ratio of the time-resolved fluorescent intensity of the detection area to the time-resolved fluorescent intensity of the quality control area, and calculating the content of vancomycin in the sample to be tested according to the obtained function formula.
    [0016] Preferably, the sample to be tested is loaded in an amount of 1-100 µL.
    [0017] Advantageous effects of the present invention: the present invention provides a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin, which uses a vancomycin-bovine serum albumin conjugate as an immunogen, and has strong specificity and good immunogenicity, and the prepared vancomycin monoclonal antibody has strong specificity and high titer. In addition, the test strip of the present invention can improve the stability of fluorescence detection, eliminate the interference of the fluorescent substance in the environment to an object to be tested, reduce the background fluorescent intensity, and improve the resolution. It has been experimentally verified that the test strip of the present invention has no cross reaction with various vancomycin analogs, and has the advantages of high detection accuracy and strong specificity. BRIEF DESCRIPTION OF THE DRAWINGS
    [0018] FIG. 1 is a graph showing the correlation analysis of the measurement results of the test strips of Embodiment 1 of the present invention in Embodiment 4. DETAILED DESCRIPTION
    [0019] The present invention provides a preparation method of a vancomycin-bovine serum albumin conjugate comprising the following steps: 1) a sodium periodate aqueous solution is mixed with a vancomycin aqueous solution to carry out a redox reaction to obtain a vancomycin pre-conjugate; 2) bovine serum albumin is mixed with a carbonate buffer to obtain a bovine serum albumin solution; and 3) the vancomycin pre-conjugate in step 1) is mixed with the bovine serum albumin solution in step 2), and a coupling reaction is carried out to obtain a vancomycin-bovine serum albumin conjugate.
    [0020] Steps 1) and 2) are not chronologically limited.
    [0021] In the present invention, the reasons for preparing the vancomycin-bovine serum albumin conjugate are that vancomycin is a small molecule substance, which is only immunoreactive, has no immunogenicity, and cannot induce an immune response in the body. Therefore, coupling vancomycin with a carrier protein makes vancomycin immunogenic. The structural formula of vancomycin (Vm) hydrochloride is as follows:
    [0022] In the present invention, the sodium periodate aqueous solution is mixed with the vancomycin aqueous solution to carry out a redox reaction to obtain a vancomycin pre-conjugate.
    [0023] In the present invention, the concentration of the sodium periodate aqueous solution is preferably 8-12 mg/mL and more preferably 10 mg/mL, and the concentration of the vancomycin aqueous solution is preferably 8-12 mg/mL and more preferably 10 mg/mL. The solvent of the vancomycin aqueous solution is preferably ultra-pure water. The volume ratio of the sodium periodate aqueous solution to the vancomycin aqueous solution is preferably 1-3:0.5-1.5 and more preferably 2:1.
    [0024] In the present invention, the time of the redox reaction is preferably 0.8-1.5 h and more preferably 1-1.2 h. the temperature of the redox reaction is preferably 18-26°C and more preferably 20°C. The redox reaction is preferably carried out in the dark. The redox reaction is preferably carried out under stirring. The stirring speed is preferably 500-3,000 rpm, more preferably 800-2,000 rpm, and most preferably 1,500 rpm.
    [0025] In the present invention, the bovine serum albumin is mixed with the carbonate buffer to obtain a bovine serum albumin solution.
    [0026] In the present invention, the mass/volume ratio of the bovine serum albumin to the carbonate buffer is 4-6 mg:0.5-1.5 mL and more preferably 5 mg:1 mL. The concentration of the carbonate buffer is preferably 40-60 mmol/L and more preferably 50 mmol/L. The pH of the carbonate buffer is preferably 9.4-9.8 and more preferably 9.6. The mixing temperature is preferably 15-37°C, more preferably 20-30°C, and most preferably 25°C. The mixing time is preferably 0.5-3 h, more preferably 1-2 h, and most preferably 1.5 h.
    [0027] In the present invention, after the vancomycin pre-conjugate and the bovine serum albumin solution are obtained, the vancomycin pre-conjugate is mixed with the bovine serum albumin solution to carry out a coupling reaction to obtain a vancomycin-bovine serum albumin conjugate.
    [0028] In the present invention, the volume ratio of the vancomycin pre-conjugate to the bovine serum albumin solution is preferably 1-2:0.5-1.5 and more preferably 1.5:1. The time of the coupling reaction is preferably 10-15 h and more preferably 12 h. The temperature of the coupling reaction is preferably 15-37°C and more preferably 25°C. The coupling reaction is preferably carried out under stirring. The stirring speed is preferably 500-3,000 rpm, more preferably 800-2,000 rpm, and most preferably 1,500 rpm.
    [0029] After the vancomycin pre-conjugate is mixed with the bovine serum albumin solution, the present invention preferably further includes adjusting the pH. The adjusted pH is preferably 8.5-9.5 and more preferably 9. The reagent for adjusting the pH is preferably a sodium carbonate solution. The concentration of the sodium carbonate solution is preferably 0.5-1.5 mol/L and more preferably 1 mol/L.
    [0030] After the coupling reaction, the present invention preferably further includes dialyzing the coupling reactant against water, using an 8K interception dialysis bag for more than 12 h per dialysis to remove unreacted vancomycin molecules and a coupling agent. The number of times of dialysis against water is preferably 3-7, and more preferably 5.
    [0031] After the vancomycin-bovine serum albumin conjugate is obtained by the present invention, the vancomycin-bovine serum albumin conjugate is preferably stored at -40°C to -80°C and more preferably -70°C.
    [0032] After the vancomycin-bovine serum albumin conjugate is obtained, the present invention preferably further includes: identifying the vancomycin-bovine serum albumin conjugate. The method for identifying includes the following steps: the molecular weight of the vancomycin-bovine serum albumin conjugate is compared with that of bovine serum albumin. It is indicated that vancomycin has been successfully coupled to bovine serum albumin when the molecular weight of the vancomycin-bovine serum albumin conjugate is significantly greater than that of bovine serum albumin. The manner of molecular weight determination is preferably Native SDS-PAGE electrophoresis.
    [0033] The present invention provides a vancomycin-bovine serum albumin conjugate prepared by the preparation method according to the foregoing solution. The vancomycin conjugate is immunogenic and can be used as an immunogen for preparing a vancomycin monoclonal antibody.
    [0034] The present invention provides a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin, comprising a bottom plate and a sample absorption pad, a fluorescent microsphere pad, a nitrocellulose membrane coated with an antibody, and an absorbent pad which are sequentially overlapped and pasted on the bottom plate.
    [0035] In the present invention, the test strip is preferably assembled by the following method: the sample absorption pad, the fluorescent microsphere pad, the nitrocellulose membrane coated with the vancomycin-carrier protein conjugate, and the absorbent pad are overlapped and pasted onto the bottom plate sequentially from left to right, where the end of the sample absorption pad is connected to the beginning of the fluorescent microsphere pad, the end of the fluorescent microsphere pad is connected to the beginning of the nitrocellulose membrane coated with the vancomycin-carrier protein conjugate, the end of the nitrocellulose membrane coated with the vancomycin-carrier protein conjugate is connected to the beginning of the absorbent pad, the beginning of the sample absorption pad is aligned with the beginning of the bottom plate, and the end of the absorbent pad is aligned with the end of the bottom plate, and then cut into small strips by a machine to be packed in a special plastic card to form a test strip, the width of the small strip is preferably 3.8-4 mm and more preferably 3.96 mm.
    [0036] In the present invention, the sample absorption pad is preferably prepared by the following method, including the following steps: the absorbent pad is placed in the bovine serum albumin solution, soaked, and dried to obtain the sample absorption pad
    [0037] In the present invention, the volume percentage of bovine serum albumin in the bovine serum albumin solution is preferably 0.3-0.8% and more preferably 0.5%. The solvent of the bovine serum albumin solution is preferably a phosphate buffer. The concentration of the phosphate buffer is preferably 0.05-0.15 mol/L and more preferably 0.1 mol/L. The pH of the phosphate buffer is preferably 7.1-7.5 and more preferably 7.2. The soaking time is preferably 1.5-2.5 h and more preferably 2 h. The soaking temperature is preferably 15-37°C and more preferably 25°C. The drying temperature is preferably 35-40°C and more preferably 37°C. The drying time is preferably 1-3 h and more preferably 2 h. The drying mode is preferably oven-drying.
    [0038] In the present invention, the fluorescent microsphere pad is sprayed with the fluorescent microsphere-labeled vancomycin monoclonal antibody. The fluorescent microsphere pad is preferably prepared by the following method: the fluorescent microsphere-labeled vancomycin monoclonal antibody is loaded to a glass cellulose membrane and dried to obtain a fluorescent microsphere pad; the fluorescent microsphere-labeled vancomycin monoclonal antibody is preferably added in an amount of 10-100 µg, more preferably 20-50 µg, and most preferably 30 µg; a loading device of the fluorescent microsphere-labeled vancomycin monoclonal antibody is preferably a gold-standard film sprayer; the drying time is preferably 12-18 h and more preferably 15 h; and the drying temperature is preferably 35-40°C and more preferably 37°C.
    [0039] In the present invention, the fluorescent microsphere-labeled vancomycin monoclonal antibody is preferably prepared by the following method: I. A fluorescent microsphere suspension, an MES buffer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide are mixed for activation treatment to obtain an activated fluorescent microsphere. II. The activated fluorescent microsphere in step I is mixed with the vancomycin monoclonal antibody for coupling to obtain a fluorescent microsphere-labeled vancomycin monoclonal antibody.
    [0040] In the present invention, the fluorescent microsphere suspension, the MES buffer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide are mixed for activation treatment to obtain an activated fluorescent microsphere.
    [0041] In the present invention, the diameter of the fluorescent microsphere is 100-300 nm, more preferably 150-280 nm, and most preferably 200 nm. Preferably, the fluorescent microsphere has a carboxyl group on the surface. The fluorescent microsphere is preferably a microsphere in which polystyrene is coated with rare earth ion Eu+. The content of the fluorescent microsphere in the fluorescent microsphere suspension is preferably 1% (W/V).The concentration of the MES is preferably 40-60 mM and more preferably 50 mM. The pH of the MES buffer is preferably 5.5-6.5 and more preferably 6. The ratio of the fluorescent microsphere suspension, the MES buffer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide is 80-120 µL:300-500 µL:0.3-1 mg:0.3-1 mg and more preferably 100 µL:400 µL:0.5 mg:0.5 mg. In the present invention, the time for activation treatment is preferably 10-20 min and more preferably 15 min. The temperature for activation treatment is preferably 18-26°C and more preferably 20°C. The activation treatment is preferably carried out in an oscillating condition.
    [0042] After the activated fluorescent microsphere is obtained, the present invention preferably further includes centrifuging the activated fluorescent microsphere, and re-suspending precipitates. The centrifugal rotation speed is preferably 8,000-12,000 rpm and more preferably 10,000 rpm. The centrifuging temperature is preferably 0-5°C and more preferably 4°C. The centrifuging time is preferably 8-12 min and more preferably 10 min. The solvent for re-suspending precipitates is preferably the MES buffer.
    [0043] In the present invention, the activated fluorescent microsphere is mixed with the vancomycin monoclonal antibody for coupling to obtain a fluorescent microsphere-labeled vancomycin monoclonal antibody.
    [0044] In the present invention, the volume mass ratio of the activated fluorescent microsphere to the vancomycin monoclonal antibody is preferably 400-600 µL:1-3 µg and more preferably 500 µE:2 µg. The time for coupling is preferably 100-150 min and more preferably 120 min. The temperature for coupling is preferably 18-26°C and more preferably 20°C. The coupling is preferably carried out in an oscillating condition.
    [0045] After the fluorescent microsphere-labeled vancomycin monoclonal antibody is obtained, the present invention preferably further includes: the fluorescent microsphere-labeled vancomycin monoclonal antibody is mixed with the bovine serum albumin aqueous solution for a blocking treatment to obtain a blocked fluorescent microsphere-labeled vancomycin monoclonal antibody. The volume ratio of the fluorescent microsphere-labeled vancomycin monoclonal antibody to the bovine serum albumin aqueous solution is preferably 4-6:0.5-1.5 and more preferably 5:1 The mass percentage of bovine serum albumin in the bovine serum albumin aqueous solution is preferably 8-12% and more preferably 10%. The blocking temperature is preferably 18-26 °C and more preferably 20°C. The blocking time is preferably 10-15 h and more preferably 12 h.
    [0046] In the present invention, the method for storing the blocked fluorescent microsphere-labeled vancomycin monoclonal antibody includes the following steps: the blocked fluorescent microsphere-labeled vancomycin monoclonal antibody is centrifuged, precipitates are re-suspended and washed, and then saved. In the present invention, the centrifugal rotation speed is preferably 8,000-12,000 rpm and more preferably 10,000 rpm. The centrifuging temperature is preferably 0-5°C and more preferably 4°C. The centrifuging time is preferably 8-12 min and more preferably 10 min. The solvent for re-suspending the precipitates is preferably a storage buffer. The storage buffer is preferably a phosphate buffer containing NaN3 and bovine serum albumin. The mass percentage of NaN3 in the phosphate buffer is preferably 0.01-0.02%. The mass percentage of bovine serum albumin in the phosphate buffer is preferably 0.1-0.2%. The pH of the phosphate buffer is preferably 7.2-7.5 and more preferably 7.4. The number of times of washing precipitates is preferably 1-2. The method for washing precipitates includes centrifuging again, and re-suspending the precipitates. The temperature of storage is preferably 0-5°C and more preferably 4°C. The storage is preferably carried out in the dark.
    [0047] In the present invention, preferably, the vancomycin monoclonal antibody is prepared by using the vancomycin-bovine serum albumin conjugate as described in the scheme as an immunogen and more preferably, the vancomycin monoclonal antibody is prepared by the following method: i) the vancomycin-bovine serum albumin conjugate as described in the scheme is used as an immunogen to immunize a first Balb/c mouse, and immunization is boosted to obtain Balb/c mouse spleen cells capable of producing specific antibodies; ii) the Balb/c mouse spleen cells capable of producing specific antibodies in step i) are fused with myeloma cells SP20, a cell supernatant is determined, and positive wells are screened; iii) cloning the fused cells in the positive wells in step ii) to obtain monoclonal antibody-producing hybridoma cells; iv) the hybridoma cells in step iii) are intraperitoneally injected after the sterilized paraffin oil is injected into the abdominal cavity of a second Balb/c mouse, and ascites is collected and purified to obtain a vancomycin monoclonal antibody.
    [0048] In the present invention, the first Balb/c mouse is immunized by using the vancomycin-bovine serum albumin conjugate as the immunogen as described in the scheme, to obtain Balb/c mouse spleen cells capable of producing specific antibodies.
    [0049] The present invention has no special limitation to the immunization method, and the conventional immunization methods in the art can be used. The present invention has no special requirement for the number of booster immunizations and the dosage of vancomycin-bovine serum albumin conjugate for each booster immunization on the basis that the first Balb/c mouse can produce specific antibodies. The present invention has no special limitation to the method for obtaining Balb/c mouse spleen cells capable of producing specific antibodies, and the conventional immunization methods in the art can be used.
    [0050] In the present invention, after Balb/c mouse spleen cells capable of producing specific antibodies are obtained, the Balb/c mouse spleen cells capable of producing specific antibodies are fused with myeloma cells SP20, the cell supernatant is determined, and positive wells are screened.
    [0051] In the present invention, the method for determining the cell supernatant is preferably an indirect competitive enzyme-linked immunoassay. The present invention has no special limitation to the method for screening the positive wells, and the conventional screening methods in the art can be used.
    [0052] In the present invention, after the positive wells are obtained, the fused cells in the positive wells are cloned to obtain monoclonal antibody-producing hybridoma cells. The present invention has no special limitation to the method for cloning, and the conventional methods in the art can be used.
    [0053] In the present invention, after the hybridoma cells are obtained, the hybridoma cells are intraperitoneally injected after the sterilized paraffin oil is injected into the abdominal cavity of the second Balb/c mouse, and ascites is collected and purified to obtain the vancomycin monoclonal antibody.
    [0054] In the present invention, the age of the second Balb/c mouse is preferably 7-9 weeks old and more preferably 8 weeks old. The present invention has no special limitation to the injection amount of the sterilized paraffin oil, and the conventional dosages in the art can be used. The time interval between the intraperitoneal injection of the sterile paraffin oil in the second Balb/c mouse and the intraperitoneal injection of the hybridoma cells is preferably 7-14 d and more preferably 10-12 d. The time interval between the intraperitoneal injection of the hybridoma cells and the ascites collection is preferably 7-10 d and more preferably 8-9 d. The method for purifying ascites is preferably an octanoic acid-saturated ammonium sulfate method.
    [0055] After the ascites is purified, the present invention preferably further includes the purity identification of the vancomycin monoclonal antibody. The method for identification is preferably SDS-PAGE electrophoresis.
    [0056] In the specific implementation process of the present invention, the storage temperature of the vancomycin monoclonal antibody is preferably from -15°C to -30°C and more preferably -20°C.
    [0057] In the present invention, the nitrocellulose membrane coated with the vancomycin-carrier protein conjugate preferably includes a detection area (T) and a quality control area (C). The detection area is preferably coated with a vancomycin-chicken egg albumin conjugate, and the quality control area is preferably coated with a goat anti mouse antibody. In the present invention, the nitrocellulose membrane coated with the vancomycin-carrier protein conjugate is preferably prepared by the following method: the detection area is coated with the vancomycin-chicken egg albumin conjugate, the quality control area is coated with the goat anti mouse antibody, and dried to obtain a nitrocellulose membrane coated with the vancomycin-carrier protein conjugate. The drying temperature is preferably 35-40°C and more preferably 37°C; the drying time is preferably 4-6 h and more preferably 5 h.
    [0058] In the present invention, coating the detection area with the vancomycin-chicken egg albumin conjugate is preferably carried out by the following method: the vancomycin-chicken egg albumin conjugate is sprayed onto a detection region on the nitrocellulose membrane to form the detection area. In the present invention, the concentration of the vancomycin-chicken egg albumin conjugate is preferably 150-280 µg/mL and more preferably 200 µg/mL. The spraying amount of the vancomycin-chicken egg albumin conjugate is preferably 1-1.5 µL/cm and more preferably 1.2 µL/cm. The spraying device is preferably a gold-standard film sprayer. In the present invention, the vancomycin-chicken egg albumin conjugate is sprayed to the front of the detection area on the nitrocellulose membrane, preferably including diluting the vancomycin-chicken egg albumin conjugate. The dilute solution is preferably a phosphate buffer. The concentration of the phosphate buffer is preferably 0.03-0.08 mol/L and more preferably 0.05 mol/L. The pH of the phosphate buffer is preferably 7.0-7.5 and more preferably 7.2.
    [0059] In the present invention, the vancomycin-chicken egg albumin conjugate is preferably prepared by the following method: 1) the chicken egg albumin is mixed with the phosphate buffer to obtain a chicken egg albumin solution; and 2) the chicken egg albumin solution in step 1) vancomycin, 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide, and N-hydroxythiosuccinimide are mixed for a coupling reaction, and the coupled product is dialyzed against water to obtain a vancomycin-chicken egg albumin conjugate.
    [0060] In the present invention, the chicken egg albumin is mixed with the phosphate buffer to obtain a chicken egg albumin solution.
    [0061] In the present invention, the mass/volume ratio of the chicken egg albumin to the phosphate buffer is 8-12 mg:1-3 mL and more preferably 10 mg:2 mL. The concentration of the phosphate buffer is preferably 0.05-0.15 M and more preferably 0.1 M. The pH of the phosphate buffer is preferably 7.2-7.5 and more preferably 7.4.
    [0062] In the present invention, after the chicken egg albumin solution is obtained, the chicken egg albumin solution, vancomycin, 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide, and N-hydroxythiosuccinimide are mixed for a coupling reaction, and the coupled product is dialyzed against water to obtain a vancomycin-chicken egg albumin conjugate.
    [0063] In the present invention, the ratio of the chicken egg albumin solution, vancomycin, 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide, and N-hydroxythiosuccinimide is preferably 1-3 mL:8-12 mg:2-4 mg:4-6 mg and more preferably 2 mL:10 mg:3 mg:5 mg. The coupling time is preferably 0.5-1.5 h and more preferably 1 h. The coupling temperature is preferably 18-26°C and more preferably 20°C. The coupling reaction is preferably carried out under stirring. The number of times of dialysis against water is preferably 3-7 and more preferably 5. The storage temperature of the vancomycin-chicken egg albumin conjugate is preferably from -40°C to -80°C and more preferably -70°C.
    [0064] After the vancomycin-chicken egg albumin conjugate is obtained, the present invention preferably further includes identifying the vancomycin-chicken egg albumin conjugate. The method for identifying includes the following steps: comparing the molecular weight of the vancomycin-chicken egg albumin with that of the chicken egg albumin. If the molecular weight of the vancomycin-chicken egg albumin conjugate is significantly greater than that of the chicken egg albumin, it is indicated that vancomycin has been successfully coupled to the chicken egg albumin. The method for determining the molecular weight is preferably Native SDS-PAGE electrophoresis.
    [0065] In the present invention, coating the quality control area with the goat anti mouse antibody is preferably carried out by the following method: spraying the goat anti mouse antibody onto the quality control area on the nitrocellulose membrane to form the quality control area. In the present invention, the concentration of the goat anti mouse antibody is preferably 150-280 µg/mL and more preferably 200 µg/mL; and the spraying amount of the goat anti mouse antibody is preferably 1.0-1.5 µL/cm and more preferably 1.2 µL/cm. The spraying device is preferably a gold-standard film sprayer. Before the goat anti mouse antibody is sprayed onto the quality control area on the nitrocellulose membrane, the present invention preferably includes: the goat anti mouse antibody is diluted. The dilute solution is preferably a phosphate buffer. The concentration of the phosphate buffer is preferably 0.03-0.08 mol/L and more preferably 0.05 mol/L; and the pH of the phosphate buffer is preferably 7.0-7.5 and more preferably 7.2.
    [0066] The present invention also provides an application of the test strips described in the scheme in the detection of vancomycin, including the following steps:pure vancomycin of different concentrations is added to a human serum matrix excluding vancomycin to prepare a calibrator, where the concentrations of vancomycin in the calibrator is 40 µg/mL, 20 µg/mL, 10 µg/mL, 5 µg/mL, and 0µg/mL, sequentially; the calibrator is diluted 100-1,000 times, and then loaded to a sample absorption pad of the test strip for immunochromatography, and a ratio (a T/C ratio) of the time-resolved fluorescent intensity of the detection area to the time-resolved fluorescent intensity of the quality control area is determined to obtain a function relation of the concentration of the calibrator and the T/C ratio.
    [0067] A sample to be tested is taken and loaded to the sample absorption pad of the test strip for immunochromatography, a ratio of the time-resolved fluorescent intensity of the detection area to the time-resolved fluorescent intensity of the quality control area is determined, and the content of vancomycin in the sample to be tested is calculated according to the obtained function formula.
    [0068] In the present invention, if the fluorescence signal intensity is not detected in the quality control area, it is indicated that the operation process is incorrect or the test strip is expired.
    [0069] In the present invention, the sample to be tested is preferably added in an amount of 1-100 µL, more preferably 20-90 µL, and most preferably 80 µL. The time of the immunochromatography is preferably 10-20 min and more preferably 15 min. The temperature of the immunochromatography is preferably 20-25°C and more preferably 22-24°C. The device for determining the ratio of the time-resolved fluorescent intensity of the detection area to the time-resolved fluorescent intensity of the quality control area is preferably a fluorescence detector.
    [0070] The time-resolved fluorescent immunochromatographic test strip for detecting vancomycin as well as the preparation method and application thereof provided by the present invention are described in detail below with reference to embodiments. However, the embodiments shall not be construed as limiting the protection scope of the present invention. Embodiment 1A preparation method of a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin1. Synthesis and identification of the vancomycin hapten-carrier protein conjugate(1) Preparation of the vancomycin-bovine serum albumin conjugate:
    [0071] 0.5 mL of ultrapure water in which 5 mg vancomycin is dissolved is added in 1 mL of 10 mg/mL NaIO4 solution, and the reaction is carried out by stirring at room temperature for 1 h in the dark. The reaction mixture is added to 1 ml of 5 mg/mL bovine serum albumin solution (50 mmol/L carbonate buffer with the pH of 9.6), adjusted to pH 9 with 1 mol/L Na2CO3 solution, stirred for 12 h, and dialyzed against water for 5 times, and stored at -70°C for future use. (2) Preparation of the vancomycin-chicken egg albumin conjugate:
    [0072] 10 mg of chicken egg albumin is dissolved in 2 mL of 0.1 M phosphate buffer with the pH of 7.4, 10 mg of vancomycin is added to the foregoing solution to be uniformly stirred, and then 3 mg of 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide and 5 mg of N-hydroxythiosuccinimide are added and dissolved in the foregoing solution, and stirred at room temperature and reacted for 1 h. Dialysis against water is carried out for 5 times, and storage is carried out at -70°C. (3) Identification of vancomycin hapten-carrier protein conjugate
    [0073] Molecular weight analysis of four proteins, i.e., the bovine serum albumin, the vancomycin-bovine serum albumin conjugate, the chicken egg albumin, and the vancomycin-chicken egg albumin conjugate, is simultaneously performed by Native SDS-PAGE electrophoresis. The results show that the molecular weight of the vancomycin-bovine serum albumin ovalbumin peptide is significantly greater than that of the bovine serum albumin, and the molecular weight of the vancomycin-chicken egg albumin ovalbumin peptide is significantly higher than that of the chicken egg albumin, indicating that vancomycin has been successfully coupled to the bovine serum albumin and the chicken egg albumin. 2. Preparation of the vancomycin monoclonal antibody
    [0074] The prepared vancomycin-bovine serum albumin immunogen is immunized with Balb/c by a conventional method, and the Balb/c mouse spleen cells which produce specific antibodies are fused with myeloma cells SP20 after intensive immunization, and an indirect competitive enzyme-linked immunoassay method is used to determine the cell supernatant, and positive wells are screened. The positive wells are cloned by using a limiting dilution method to obtain and establish a monoclonal antibody-producing hybridoma cell line.
    [0075] Balb/c mice (8 weeks old) are intraperitoneally injected with sterile paraffin oil, and hybridoma cells are intraperitoneally injected 7-14 days later, and ascites is collected 7-10 days later. The ascites is purified by the octanoic acid-saturated ammonium sulfate method, the purity is identified by SDS-PAGE electrophoresis, and storage is carried out at -20°C. 3. Preparation of the fluorescent microsphere labeled vancomycin monoclonal antibody
    [0076] (1) Activation: 100 uL of microsphere suspension internally embedded with a fluorescent dye and modified with a carboxyl functional group at the surface purchased from Nanjing Microdetection Bio-Tech Co., Ltd. is suspended in 400 uL of activation buffer (50 mM MES with the pH of 6.0), and 0.5 mg of EDC and 0.5 mg of NHS are added, and the mixture is shaken and activated at room temperature for 15 min after mixing.(2) Coupling: the suspension of (1) is centrifuged at 4°C, 10,000 r/min for 10 min, the supernatant is discarded, re-suspension is carried out in the activation buffer, 2 ug of vancomycin monoclonal antibody solution is added, and the mixture is shaken and coupled at room temperature for 120 min after mixing.(3) Blocking: the suspension of (2) is added to 100 ul of 10% bovine serum albumin solution, and the mixture is shaken and blocked overnight at room temperature after mixing.(4) Storage: the suspension of (3) is centrifuged at 4°C, 10,000 r/min for 10 min, the supernatant is discarded, and re-suspension is carried out in a storage buffer (a PB buffer containing 0.01% NaN3 and 0.1% bovine serum albumin with the pH of 7.4), the microspheres are washed once, and the mixture is stored at 4°C in the dark after mixing. 4. Preparation of the fluorescent microsphere pad
    [0077] The stored fluorescent microsphere-labeled vancomycin monoclonal antibody is diluted to 2 µg/mL in the storage buffer, and then sprayed with a gold-standard film sprayer, dried at 37°C for 15 h, and taken out and sealed for storage. 5. Preparation of a nitrocellulose (NC) membrane coated with antibodies
    [0078] The vancomycin hapten-chicken egg albumin conjugate is diluted to 200 ug/mL with 0.05 mol/L of PB buffer with the pH of 7.2, and sprayed on the detection area (T) of the NC membrane with the gold-standard film sprayer with the quantity for spray of 1.2 uL/cm; the goat anti mouse antibody is diluted to 200 ug/mL with 0.05 mol/L of PB buffer with the pH of 7.2, and sprayed onto the detection area (C) of the NC membrane with the gold-standard film sprayer with the quality for spray of 1.2 uL/cm, and dried at 37°C for 5 h for future use. 6. Preparation of a sample absorption pad
    [0079] The sample absorption pad is soaked in 0.1 mol/L of phosphate buffer with the pH of 7.2 containing 0.5% bovine serum albumin (volume fraction) for 2 h, and dried at 37°C for 2 h for future use. 7. Assembly of a test strip
    [0080] The sample absorption pad, the glass fiber pad, the NC membrane, and the absorbent pad are sequentially overlapped and immobilized from left to right on the bottom plate, the end of the sample absorption pad is connected to the beginning of the glass fiber pad, the end of the glass fiber pad is connected to the beginning of the NC membrane, the end of the NC membrane is connected to the beginning of the absorbent pad, the beginning of the sample absorption pad is aligned with the beginning of the bottom plate, and the end of the absorbent pad is aligned with the end of the bottom plate, and then cut into a small strip with a width of 3.96 mm by a machine to be packed in special plastic cards to form a test strip. Embodiment 2 Application of the test strip of Embodiment 11. Sample pretreatment
    [0081] 20 ul of sample is accurately pipetted into 180 ul of sample diluent and mixed fully. 2. Detection with the test strip
    [0082] 80 uL of sample solution to be tested is accurately pipetted into a test strip loading well with a micropipette, and reaction is carried out at 20°C for 15 min; the test strip is inserted into a load carrier of a fluorescence detector, an item to be tested is selected by touching a display screen, a "Detection Start" button is pressed, the fluorescence detector automatically scans the test strip, and a test result is read through the display screen of an instrument or printed. 3. Analysis of test resultsQuantitative detection
    [0083] After the test is completed, the instrument obtains the ratio of the time-resolved fluorescent intensity of the detection area on the test strip to the time-resolved fluorescent intensity of the quality control area, and calculates the content of vancomycin in the sample to be tested according to the following formula.Y = A − D / 1 +x / C∧ B + D ;
    [0084] Expiration: if the fluorescence signal intensity is not detected in the quality control area, it is indicated that the operation process is incorrect or the test strip is expired. Embodiment 3 Measurement of cross-reaction rate of the test strip of Embodiment 1
    [0085] Several vancomycin analogs and common drugs are selected for interference testing. The following various compounds are added to a human serum sample with the vancomycin concentration of 20 µg/mL, and the sample is tested using the test strip of Embodiment 1, and the test results of the sample added with the compound are compared with the results of the control sample. See Table 1 for the test results. The results show that the vancomycin test strip of Embodiment 1 of the present invention has high specificity and does not cross-react with various drugs. Table 1 Results of cross-reaction rate measurement of the test strip of Embodiment 1 Compound name Test concentration Cross reaction rate a Vancomycin 20 µg/mL 100% Norvancomycin 100 µg/mL <1% Salicylic acid 1,000 µg/mL <0.001% Aspirin 1,000 µg/mL <0.001% Valproic acid 1,000 µg/mL <0.001% Carbamazepine 1,000 µg/mL <0.001% Digoxin 1,000 µg/mL <0.001% Phenytoin 1,000 µg/mL <0.001% Theophylline 1,000 µg/mL <0.001% cross reaction rate = 100 × Test results of the sample added with compounds − Results of the control sample Concentration of the added cross reactant a
    [0086] The test strip of Embodiment 1 of the present invention is compared with the method for determining vancomycin in human serum by high performance liquid chromatography, where the human serum is a clinical serum sample. The high performance liquid chromatography is carried out as follows: Waters 2695 High Performance Liquid Chromatograph, C18 column (150 mm x 4.6 mm, 5 µm), mobile phase: 50 mmol/L potassium dihydrogen phosphate buffer-acetonitrile with the pH of 3.2 (90:10); detection wavelength: 230 nm; flow rate: 1 mL/min; 400 µl of serum sample is added with 50 µl of 10% zinc sulfate precipitated protein, and after centrifugation at 5000 r/min, 20 µl of the sample is taken to determine the peak height of vancomycin. The results are shown in Table 2. The correlation curve is shown in FIG. 1, which shows that the two fit well. Table 2 Comparison of the method for determining the vancomycin in human serum by the test strip of Embodiment 1 of the present invention and the high performance liquid chromatography Serum sample No. Fluorescent immunochromatography (µg/mL) High performance liquid chromatography (µg/mL) Sample 1 0.4 0.5 Sample 2 1.1 1.2 Sample 3 1.6 1.9 Sample 4 2.4 2.1 Sample 5 3.5 4.2 Sample 6 5.2 5.9 Sample 7 6.4 7.1 Sample 8 8.5 8.6 Sample 9 9.2 9.8 Sample 10 11.1 10.2 Sample 11 14.2 15.2 Sample 12 15.2 17.2 Sample 13 16 15.4 Sample 14 17 18 Sample 15 19.1 19.9 Sample 16 19.8 20 Sample 17 21 22 Sample 18 23 24 Sample 19 32 34 Sample 20 25 24 Sample 21 28 30 Sample 22 30 32 Sample 23 35 38 Sample 24 46 40 Sample 25 56.1 52
    [0087] As can be seen from the above embodiments, the present invention provides a time-resolved fluorescent immunochromatographic test strip for detecting vancomycin, which has no cross reaction with various vancomycin analogs, and has the advantages of high detection accuracy and strong specificity.
    [0088] The foregoing descriptions are only preferred implementation manners of the present invention. It should be noted that for a person of ordinary skill in the art, several improvements and modifications may further be made without departing from the principle of the present invention. These improvements and modifications should also be deemed as falling within the protection scope of the present invention.
    权利要求:
    Claims (10)
    [0001] A preparation method of a vancomycin-bovine serum albumin conjugate, comprising the following steps:
    1) mixing a sodium periodate aqueous solution with a vancomycin aqueous solution to carry out a redox reaction to obtain a vancomycin pre-conjugate;
    2) mixing bovine serum albumin with a carbonate buffer to obtain a bovine serum albumin solution; and
    3) mixing the vancomycin pre-conjugate in step 1) with the bovine serum albumin solution in step 2), and carrying out a coupling reaction to obtain a vancomycin-bovine serum albumin conjugate;steps 1) and 2) are not chronologically limited.
    [0002] The preparation method according to claim 1, wherein the time of the coupling reaction in step 3) is 10-15 h, and the temperature of the coupling reaction is 15-37°C.
    [0003] The preparation method according to claim 1 or 2, wherein the time of the redox reaction in step 1) is 0.8-1.5 h, and the temperature of the redox reaction is 18-26°C.
    [0004] A vancomycin-bovine serum albumin conjugate prepared by the preparation method according to any one of claims 1 to 3.
    [0005] A time-resolved fluorescent immunochromatographic test strip for detecting vancomycin, comprising a bottom plate and a sample absorption pad, a fluorescent microsphere pad, a nitrocellulose membrane coated with a vancomycin-carrier protein conjugate, and an absorbent pad which are sequentially overlapped and pasted on the bottom plate, wherein:the fluorescent microsphere pad is sprayed with a fluorescent microsphere-labeled vancomycin monoclonal antibody, and the vancomycin monoclonal antibody is prepared by using the vancomycin-bovine serum albumin conjugate according to claim 4 as an immunogen.
    [0006] The test strip according to claim 5, wherein the diameter of the fluorescent microsphere is 100-300 nm, and the fluorescent microsphere has a carboxyl group on the surface.
    [0007] The test strip according to claim 6, wherein the fluorescent microsphere is a microsphere in which polystyrene is coated with rare earth ion Eu+.
    [0008] The test strip according to claim 5, wherein a preparation method of the fluorescent microsphere-labeled vancomycin monoclonal antibody comprises the following steps:
    I. mixing a fluorescent microsphere suspension, an MES buffer, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and N-hydroxysuccinimide for activation treatment to obtain an activated fluorescent microsphere; and
    II. mixing the activated fluorescent microsphere in step I with the vancomycin monoclonal antibody for coupling to obtain a fluorescent microsphere-labeled vancomycin monoclonal antibody.
    [0009] An application of the test strip according to any one of claims 5 to 8 in detection of vancomycin, comprising the following steps:
    adding pure vancomycin of different concentrations to a human serum matrix excluding vancomycin to prepare a calibrator, the concentrations of vancomycin in the calibrator being 40 µg/mL, 20 µg/mL, 10 µg/mL, 5 µg/mL, and 0 µg/mL, sequentially; diluting the calibrator 100-1,000 times, and then loading to a sample absorption pad of the test strip for immunochromatography, and determining a ratio (a T/C ratio) of the time-resolved fluorescent intensity of a detection area to the time-resolved fluorescent intensity of a quality control area to obtain a function relation of the concentration of the calibrator and the T/C ratio; and
    taking a sample to be tested, and loading same to the sample absorption pad of the test strip for immunochromatography, determining a ratio of the time-resolved fluorescent intensity of the detection area to the time-resolved fluorescent intensity of the quality control area, and calculating the content of vancomycin in the sample to be tested according to the obtained function formula.
    [0010] The application according to claim 9, wherein the sample to be tested is loaded in an amount of 1-100 µL.
    类似技术:
    公开号 | 公开日 | 专利标题
    CN104204802B|2016-06-22|Immunochromatography detection method
    Unanue et al.1967|Experimental allergic glomerulonephritis induced in the rabbit with heterologous renal antigens
    FI95627B|1995-11-15|Method and kit for the determination of endotoxin or endotoxin-like substance in a sample and monoclonal antibodies for use in the method
    US4376110A|1983-03-08|Immunometric assays using monoclonal antibodies
    EP0668504B1|2001-03-21|Quaternary ammonium immunogenic conjugates and immunoassay reagent
    US4751190A|1988-06-14|Fluorescence polarization immunoassay and reagents for use therein
    EP0143274B1|1988-01-13|Heterogeneous immunoassay for digoxin using ouabain as a separation means
    McPhaul et al.1969|The presence of anti-glomerular basement membrane antibodies in peripheral blood
    KR100303525B1|2001-11-22|Immunologically Simple Semi-quantitative Method and Apparatus
    US4727022A|1988-02-23|Methods for modulating ligand-receptor interactions and their application
    US5202234A|1993-04-13|Myocardial infarction immunoassay
    US20200240991A1|2020-07-30|Levetiracetam Immunoassays
    US5573957A|1996-11-12|Monoclonal antibody to human cardiac myoglobin
    EP0280211B1|1994-11-02|Method for determination of antibodies
    US4200436A|1980-04-29|Immunochemical measuring process
    EP1864129B1|2010-08-04|Doxorubicin immunoassay
    CN101806804B|2013-10-16|Reagent for detecting acute myocardial infarction by immunological method and test strip
    CN103575893B|2016-06-15|A kind of method of quick detection saxitoxin
    EP1628136A1|2006-02-22|Method of diagnosis of disease using copeptin
    US4504587A|1985-03-12|Procedure for immunologic determination of procollagen peptide | and procollagen peptide col 1 | together and a process for preparing anti-procollagen peptide col 1 | serum
    CA2528114C|2010-12-21|Monoclonal antibodies specific for buprenorphine and metabolites thereof
    US7951545B2|2011-05-31|Method for detecting lysosomal storage diseases
    CN102879583B|2014-11-19|Test card for rapidly diagnosing pancreatic trauma and acute pancreatitis
    US7459281B2|2008-12-02|Docetaxel immunoassay
    US4469796A|1984-09-04|Assaying methods involving biospecific affinity reactions
    同族专利:
    公开号 | 公开日
    CN109813693A|2019-05-28|
    US20200217860A1|2020-07-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2020-06-12| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-06-12| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-07-15| AX| Request for extension of the european patent|Extension state: BA ME |
    2020-07-15| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-07-15| 17P| Request for examination filed|Effective date: 20190508 |
    2020-09-25| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: EXAMINATION IS IN PROGRESS |
    2020-09-30| RBV| Designated contracting states (corrected)|Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-10-28| 17Q| First examination report despatched|Effective date: 20200929 |
    2020-11-27| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: EXAMINATION IS IN PROGRESS |
    2021-03-23| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: GRANT OF PATENT IS INTENDED |
    2021-03-23| GRAP| Despatch of communication of intention to grant a patent|Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
    2021-04-21| INTG| Intention to grant announced|Effective date: 20210323 |
    2021-05-07| GRAS| Grant fee paid|Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
    2021-05-14| GRAA| (expected) grant|Free format text: ORIGINAL CODE: 0009210 |
    2021-05-14| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
    2021-06-16| AK| Designated contracting states|Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2021-06-16| REG| Reference to a national code|Ref country code: GB Ref legal event code: FG4D |
    2021-06-30| REG| Reference to a national code|Ref country code: CH Ref legal event code: EP |
    2021-07-08| REG| Reference to a national code|Ref country code: DE Ref legal event code: R096 Ref document number: 602019005331 Country of ref document: DE |
    2021-07-15| REG| Reference to a national code|Ref country code: AT Ref legal event code: REF Ref document number: 1402768 Country of ref document: AT Kind code of ref document: T Effective date: 20210715 |
    2021-07-21| REG| Reference to a national code|Ref country code: IE Ref legal event code: FG4D |
    2021-10-11| REG| Reference to a national code|Ref country code: LT Ref legal event code: MG9D |
    2021-10-29| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210916 |
    2021-11-15| REG| Reference to a national code|Ref country code: AT Ref legal event code: MK05 Ref document number: 1402768 Country of ref document: AT Kind code of ref document: T Effective date: 20210616 |
    2021-11-24| REG| Reference to a national code|Ref country code: NL Ref legal event code: MP Effective date: 20210616 |
    2021-11-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210917 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210916 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 |
    2022-01-31| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211018 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 |
    2022-02-28| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210616 |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]